Study Summary
Prospectively evaluate the safety and effectiveness of CD19/CD22 dual-target CAR-T cells in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.
Want to learn more about this trial?
Request More InfoInterventions
Dual target CAR-T cell therapyBIOLOGICAL
CD19/CD22 dual target CAR-T cell therapy
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Shenzhen University General hospital | Shenzhen | Guangdong | China |